Leukemia and lymphoma
D. John Bergsagel, MD: Clinical trials in leukemia and lymphoma
Kevin D. Bunting, PhD, Research Director of Leukemia and Lymphoma: Studies of normal cytokine signaling in hematopoiesis and dysregulated signaling associated with inflammation and cancer
Sharon Castellino, MD: Hodgkin lymphoma and survivorship
Deborah DeRyckere, PhD: Preclinical development of novel small molecule MerTK inhibitors for oncology applications, TAM-family receptor tyrosine signaling and biology, murine xenograft models of acute leukemia
Kavita Dhodapkar, MD, PhD, Translational Research Director: Mechanisms of immune regulation, in the context of autoimmunity as well as tumor immunity, in-vivo effects of immune checkpoint blocking therapies, including the role for B cells in development of autoimmunity following treatment with these agents, methods to boost anti- tumor immunity using dendritic cells
Douglas K. Graham, MD, PhD, Division Director: Developing novel therapeutics for pediatric cancer, recently validating MerTK as a novel cancer agent in leukemia, melanoma, nonsmall cell lung cancer and glioblastoma
Lubing Gu, MD: Molecular mechanisms of drug resistance in childhood cancer and leukemia
Curtis Henry, PhD: Research focuses on understanding how chronic inflammation associated with aging and obesity impacts leukemia development and therapeutic responses
Frank G. Keller, MD, Clinical Director of Leukemia: Principle investigator of COG trial for low-risk Hodgkin’s disease and clinical trials in Hodgkin’s disease, non-Hodgkin’s lymphoma and leukemia
Glen Lew, MD: Study chair of COG Phase III trial for relapsed acute lymphoblastic leukemia (ALL) and etiology, treatment and outcomes in childhood ALL
Tamara Miller, MD, MSCE: Leukemia and lymphoma, general oncology and adverse events
Melinda Pauly, MD, Director of Leukemia and Lymphoma: Relationship of the BCL-2 family of proteins within the intrinsic apoptotic pathway to members of the autophagy pathway
Christopher Porter, MD: Cancer genetics and leukemia research
Cheng-Kui Qu, MD, PhD: Cell signaling and metabolic regulation of hematopoietic stem cells focusing on the role of protein and lipid phosphatases in normal hematopoietic cell development and leukemogenesis, and development of novel therapeutics for phosphatases-associated blood disorders, such as juvenile myelomonocytic leukemia
Himalee Sabnis, MD, MS: Biology of acute myeloid leukemia (AML), signaling pathways in leukemic cells and new therapeutic agents in AML
Zhengqi Wang, PhD: Study of STAT5 and its function in signaling mechanisms in leukemogenesis, hematopoietic stem cell biology and transplant
Daniel Wechsler, MD, PhD, Director of Oncology: Infant leukemias, pathogenesis of poor prognosis CALM-associated leukemias and MYC antagonism in neuroblastoma
William G. Woods, MD: Clinical trials within COG in myeloid leukemia
Dan Yan, PhD: The role of MerTK on human non-small-cell lung cancer
Muxiang Zhou, MD: Signaling pathways and regulators of apoptosis relating to drug resistance in ALL
Palliative care
Katharine Brock, MD, MS: Clinical research in palliative care, assessing, and improving access and quality of pediatric palliative care within oncology, and the metrics and outcomes associated with a pediatric supportive
care clinic
Solid tumors
Thomas Cash, MD, MSc, Clinical Director of Solid Tumors: Outcomes and epidemiology in rare pediatric tumors; the role of ezrin and tumor necrosis in patients with Ewing Sarcoma, and innovative therapy and Phase I and II trials
Bradley A. George, MD: Solid tumors and histiocytosis
Kelly Goldsmith, MD: Basic and translational research of neuroblastoma, with a primary focus on mechanisms of therapy resistance
Sarah Mitchell, MD: Solid tumors and rare tumors, underlying hereditary cancer syndrome
Thomas A. Olson, MD, Program Director: Committee chair for COG germ cell disease, clinical trials in germ cell tumors, retinoblastoma and bone tumors
Robert Schnepp, MD, PhD: Research with a major emphasis on high-risk neuroblastoma and rhabdomyosarcoma employing a number of techniques, including cell and molecular biology, animal modeling, interrogation of genomic datasets with clinical annotation and functional genomics
Kathryn Sutton, MD: Clinical researcher in solid tumors, including sarcomas, rare tumors and histiocytosis
Karen Wasilewski, MD, MPH, Overall Clinical Director: survivorship and solid tumors clinical trials
Neuro-oncology
Dolly Aguilera, MD: Development of Phase I and II clinical trials for children with recurrent brain tumors
Robert C. Castellino, MD: Pediatric neuro-oncology, interactions between p53/Hedgehog/and PI-3 Kinase cell signaling in neuronal development, brain tumor development or progression, and as targets for drug development
Jason Fangusaro, MD, Director of Developmental Therapeutics
Delores Hambardzumyan, PhD: Investigating the role of the brain microenvironment in how it contributes to pediatric and adult glioblastoma growth and response to therapy
Anna J. Janss, MD, PhD: Phase I COG clinical trials and innovative therapeutics for brain tumors
Anna M. Kenney, PhD: How Sonic hedgehog and interacting signal transduction pathways control normal and neoplastic development within the cerebellum
Tobey J. MacDonald, MD, Director of Neuro-oncology: Basic and translational research of childhood brain tumors with a primary research focus on the metastasis and role of platelet-derived growth factor receptor (PDGFR) signaling
Claire M. Mazewski, MD: Principal investigator of COG high-risk medulloblastoma trial for young children, clinical trials, innovative therapeutics and late effects studies for children with brain tumors
Hospitalists
Kirshma Khemani, MD: Benign Hematology, Sickle Cell Disease and post-transplant late effects.
Joanna Newton, MD: Racial and ethnic disparities in pediatric AML outcomes, and expression of CD36 and the presence of cytoplasmic granules in blasts predicts poor prognosis in children with B-lymphoblastic leukemia
Psychology and neuropsychology
Grace Fong, PhD: Acquired brain injury and clinical trials for late effects
Lisa Ingerski, PhD: Childhood psychology
Alcuin Johnson, PhD: Acquired brain injury, transition to adult care and motivational interviewing
James Klosky, PhD, Director of Psychology: Childhood cancer psychology
Jennifer Lee, PhD: Childhood cancer psychology
Jordan Marchak, PhD: Childhood cancer survivorship and transition to adult care
Laura Mee, PhD: Childhood cancer psychology issues with transplant patients, pain management and coping with chronic medical conditions
Soumitri Sil, PhD: Research on pediatric pain management focused on the development and evaluation of behavioral interventions to promote the health and functioning of children and adolescents with complex chronic pain conditions
Beth Thompson, PsyD: Pain management, pica and coping with chronic illness
Angela Vaz, PhD: Consultation liaison in pediatric psycho-oncology, parent-child coping with pediatric chronic illness, and chronic stress and bereavement
Cancer survivorship
Karen Effinger, MD, Clinical Director of Survivorship: Physical and psychosocial functioning in children, adolescents and young adults after cancer treatment with a particular focus in cardiovascular health, health risk behaviors, wellness and physical functioning
Lillian R. Meacham, MD, Medical Director of Survivorship: Childhood Cancer Survivor Study, educating survivors and providers about survivor care, and endocrine late effects in oncology patients
Ann C. Mertens, PhD, Research Director of Survivorship: Childhood and adolescent cancer survivorship
Briana C. Patterson, MD: Late effects of cancer therapy in brain tumor patients and endocrine problems following cancer treatment